



BRIEF REPORT

## Comparison of the identification results of *Candida* species obtained by BD Phoenix<sup>TM</sup> and Maldi-TOF (Bruker Microflex LT Biotyper 3.1)



Andrea P. Marucco<sup>a,\*</sup>, Patricia Minervini<sup>b</sup>, Gabriela V. Snitman<sup>c</sup>, Adriana Sorge<sup>d</sup>, Liliana I. Guelfand<sup>e</sup>, Laura López Moral<sup>f</sup>, Integrantes de la Red de Micología CABA<sup>1</sup>

<sup>a</sup> Hospital de Agudos Santojanni, CABA, Argentina

<sup>b</sup> Hospital Oftalmológico Santa Lucía, CABA, Argentina

<sup>c</sup> Hospital de Quemados, CABA, Argentina

<sup>d</sup> Instituto de Oncología Roffo, CABA, Argentina

<sup>e</sup> Hospital Fernández, CABA, Argentina

<sup>f</sup> Hospital Argerich, CABA, Argentina

Received 28 May 2017; accepted 15 October 2017

### KEYWORDS

BD Phoenix<sup>TM</sup>;  
Final yeast  
identification;  
*Candida* spp.

**Abstract** In patients with invasive fungal infections, the accurate and rapid identification of the genus *Candida* is of utmost importance since antimycotic sensitivity is closely related to the species. The aim of the present study was to compare the identification results of species of the genus *Candida* obtained by BD Phoenix<sup>TM</sup> (Becton Dickinson [BD]) and Maldi-TOF MS (Bruker Microflex LT Biotyper 3.1). A total of 192 isolates from the strain collection belonging to the Mycology Network of the Autonomous City of Buenos Aires, Argentina, were analyzed. The observed concordance was 95%. Only 10 strains (5%) were not correctly identified by the BD Phoenix<sup>TM</sup> system. The average identification time with the Yeast ID panels was 8 h 22 min. The BD Phoenix<sup>TM</sup> system proved to be a simple, reliable and effective method for identifying the main species of the genus *Candida*.

© 2017 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author.

E-mail address: [apmarucco27@gmail.com](mailto:apmarucco27@gmail.com) (A.P. Marucco).

<sup>1</sup> The members of the group participated in the work are listed in Appendix A.

**PALABRAS CLAVE**

BD Phoenix™;  
Identificación  
definitiva de  
levaduras;  
*Candida* spp.

## Comparación de los resultados de identificación de especies del género *Candida* obtenidos por BD Phoenix™ y Maldi-TOF (Bruker Microflex LT Biotyper 3.1)

**Resumen** En pacientes con infecciones fúngicas invasoras, la identificación certera y rápida de las especies del género *Candida* es de suma importancia, ya que la sensibilidad a los antifúngicos está íntimamente relacionada con la especie. El objetivo del presente estudio fue comparar los resultados de identificación de especies del género *Candida* obtenidos con el equipo comercial BD Phoenix™ (Becton Dickinson [BD]) y con la técnica de Maldi-TOF MS (Bruker Microflex LT Biotyper 3.1.) Se analizaron 192 aislamientos provenientes del cepario perteneciente a la Red de Micología de la Ciudad Autónoma de Buenos Aires, Argentina. La concordancia observada fue del 95%. Solo 10 cepas (5%) no fueron identificadas correctamente por el sistema BD Phoenix™. El tiempo promedio de identificación con los paneles Yeast ID fue de 8 h 22 min. El sistema BD Phoenix™ demostró ser un método simple, confiable y efectivo para la identificación de las principales especies del género *Candida*.

© 2017 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Candida albicans* continues to be the most frequent yeast isolated from clinical specimens. However, *Candida* species distribution has been changing during the last decades<sup>3,5,7</sup> and it varies based on different factors including region, patient's age group, underlying disease, prophylaxis used<sup>2,7</sup>. *Candida glabrata* is an important emergent pathogen in Northern Europe, the United States and Canada, whereas *Candida parapsilosis* prevails in Southern Europe, Asia and South America<sup>5</sup>. In developed countries *C. glabrata* ranks second, followed by *C. parapsilosis* and *Candida tropicalis*<sup>3</sup>. In Latin America, *C. parapsilosis* is found in the second place, followed by *C. tropicalis* and *C. glabrata*<sup>7</sup>. In Argentina, *C. albicans* has been reported to be in the first place, followed by *C. parapsilosis* and then *C. tropicalis* and *C. glabrata*, in studies performed by the National Mycology Network [Instituto Nacional de Microbiología C. Malbrán – Administración Nacional de Laboratorios e Institutos de Salud] and the Buenos Aires City Mycology Network<sup>2,6</sup> thus confirming the data reported for Latin America<sup>7</sup>.

Among other factors, species distribution varies depending on the different stages of the life course, as it can be observed at the extremes of the age spectrum; while *C. albicans* and *C. parapsilosis* prevail in newborns, *C. glabrata* predominates in patients over 60 years old<sup>2,7</sup>.

The importance of a definitive identification lies on the fact that certain *Candida* species can show or develop a reduced sensitivity to one or several antifungal drugs, thus leading to crucial clinical consequences<sup>4,12</sup>. A quick turnaround time for this test is critical in current clinical settings, since a rapid diagnosis would enable the prescription of a specific antifungal treatment. On the other hand, identification down to species level allows for a better understanding of the epidemiology of each healthcare facility, which is important when establishing an empirical therapy.

The conventional methodology is laborious and slow, therefore, commercial methods allowing a faster identification have been developed. These methods, such as API 20C AUX<sup>®</sup> and API ID 32C<sup>®</sup> (bioMérieux, France), and RapID™

Yeast Plus<sup>®</sup> (Remel)<sup>9,14</sup>, are based on sugar assimilation and fermentation<sup>1</sup>.

During the last decades, automated methods appropriate for microbiology laboratories have been developed. Examples of these are Microscan WalkAway RYID<sup>®</sup> (Rapid Yeast Identification), Vitek YBC<sup>®</sup> (Yeast Biochemical Card), Vitek 2 ID-YST<sup>®</sup> and BD Phoenix™ Yeast ID, which can have yeasts identified within 4–48 h. The automated microbiology system BD Phoenix™ Yeast ID has been designed for the rapid identification of clinically relevant yeasts<sup>9</sup>. The assays used in the panels are modifications of standard biochemical methods. They include tests for fermentation, oxidation, degradation and hydrolysis of various substrates, as well as single-carbon-source substrates, both chromogenic and fluorogenic. Use and degradation of specific substrates are detected by different indicator systems. Acid production from carbohydrates is detected by a change in the phenol red indicator. Chromogenic substrates contain p-nitrophenyl or p-nitroanilide compounds that produce a yellow color once its enzymatic hydrolysis has taken place. Enzymatic hydrolysis of fluorogenic substrates results in the release of a product derived from the fluorescent substance coumarin. Organisms using a single-carbon-source reduce a resazurin-based indicator<sup>10,14</sup>.

The purpose of this study was to compare the identification results obtained for different species of the genus *Candida* with either the BD Phoenix™ Yeast ID automated method or the matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (MS) method.

A collection of 192 strains of the genus *Candida*, coming from various clinical specimens processed at member hospitals of the Buenos Aires City Mycology Network, Argentina, between 2009 and 2014, was analyzed. All strains were identified by conventional methods which included: micro-morphological study in corn-meal agar (Oxoid, UK) with 1% Tween 80; chromogenic agar for yeasts (CHROMagar™ *Candida*, Paris, France); API<sup>®</sup> ID 32C or API<sup>®</sup> 20C AUX (bioMérieux, Marcy l'Etoile, France) Biochemical tests were

**Table 1** Concordance index and discrepancies obtained when comparing the BD Phoenix™ system with the MALDI-TOF

Species	BRUKER MALDI-TOF (n)	BD PHOENIX (n)	Concordance index (%)	Discrepancies
<i>C. tropicalis</i>	39	38	97	1 <i>C. utilis</i>
<i>C. guilliermondii</i>	34	32	94	1 <i>C. melibiosica</i> 1 <i>C. parapsilosis</i>
<i>C. albicans</i>	31	31	100	
<i>C. parapsilosis</i> complex	29	28	96	1 <i>C. tropicalis</i>
<i>C. glabrata</i> complex	28	27	96	1 <i>C. parapsilosis</i>
<i>C. krusei</i>	23	22	95	1 <i>C. glabrata</i>
<i>C. dubliniensis</i>	4	2	50	2 <i>C. albicans</i>
<i>C. lusitaniae</i>	3	2	66	1 <i>C. melibiosica</i>
<i>C. lipolytica</i>	1	0	0	1 <i>C. rugosa</i>
Total	192	182	95	10

**Table 2** Detection time of each *Candida* species

Species BD Phoenix	Confidence interval (%)	Detection time (range) (h)
<i>C. tropicalis</i> (n = 38)	95–99	6.34 (4.23–8.43)
<i>C. guilliermondii</i> (n = 32)	95–99	7.44 (4.43–15.67)
<i>C. albicans</i> (n = 31)	95–99	5.42 (4.23–8.45)
<i>C. parapsilosis</i> complex (n = 28)	99	8.21 (4.25–15.66)
<i>C. glabrata</i> complex (n = 27)	96–99	10.32 (8.12–15.68)
<i>C. krusei</i> (n = 22)	97–99	15.34 (8.42–15.67)
<i>C. dubliniensis</i> (n = 2)	99	4.48
<i>C. lusitaniae</i> (n = 2)	99	8.43

h, hours.

added to differentiate *C. albicans* from *Candida dubliniensis*, developmental capacity at different temperatures, production of chlamydoconidia in different substrates and production of halo of opacity in media containing Tween 80 and  $\text{CaCl}_2$ <sup>8</sup>.

Thirty-nine *C. tropicalis*, 34 *Candida guilliermondii*, 31 *C. albicans*, 29 *C. parapsilosis*, 28 *C. glabrata*, 23 *Candida krusei*, 4 *C. dubliniensis*, 3 *Candida lusitaniae* and 1 *Candida lipolytica* were tested. The strains were inoculated onto chromogenic culture media for yeasts (CHROMagar™ *Candida*) in order to confirm purity. Each isolate was sub-cultured in Sabouraud dextrose agar and incubated for 48 h, at 35 °C, before using the BD Phoenix™ Yeast ID panels as instructed by the manufacturer<sup>9</sup>. As the Phoenix system does not report confidence values lower than 90%, results with scores >90% were considered to represent acceptable identifications.

Identification results were compared with those obtained by MALDI-TOF MS (Bruker Microflex LT Biotyper 3.1). The MALDI ionization, coupled to a TOF analyzer is a soft ionization technique used in mass spectrometry, which allows the analysis of biomolecules and large organic molecules<sup>11,13</sup>.

MALDI-TOF MS was used as reference method, together with genotyping identification in those strains yielding discrepant identification results. For the molecular technique, DNA extraction was performed, followed by amplification of specific DNA portions with universal primers ITS1 (5'-TCCGTAGGTGAACCTGCGG-3') and ITS4 (5'-TCCTCCGCTTATTGATATGC-3') by PCR. Amplification products were sequenced using the Sanger method. The BLAST

tool was used for identification and the criteria established were concordance >97% and coverage of at least 99%.

*Candida krusei* ATCC 6258, *C. parapsilosis* ATCC 22019 and *C. albicans* ATCC 64548 were used as control strains.

Among the different species studied, concordance was variable and rates are detailed in Table 1. The general concordance index was 95%. While *C. albicans* showed a concordance rate of 100%, the remaining species evidenced at least one discrepancy with the reference method. Ten strains (5%) were misidentified with the Yeast ID panels: one *C. tropicalis*, two *C. guilliermondii*, one *C. parapsilosis*, one *C. krusei*, two *C. dubliniensis*, one *C. lusitaniae* and one *C. lipolytica*. The low concordance rates obtained for the last three species mentioned above can be due to the low number of strains tested. For the remaining species studied the index was ≥96%.

Detection turnaround times for each of the species are shown in Table 2, with a mean time of 8 h 22 min (range 4 h 23 min–15 h 68 min). MALDI-TOF MS differentiated two of the species of the *C. parapsilosis* complex as *Candida orthopsilosis* and one species of the *C. glabrata* complex as *Candida bracarensis*. The BD Phoenix™ system did not differentiate the cryptic species from those complexes, because it is a method that identifies microorganisms based on the phenotypic features of yeasts.

According to the results obtained, we can conclude that the BD Phoenix™ Yeast ID panel system is a reliable, useful and rapid method for routine identification of the yeast species most frequently isolated from clinical specimens. Since mass spectrometry methods such as MALDI-TOF are not

available in most clinical microbiology laboratories, the BD Phoenix™ system offers an effective alternative. It is noteworthy that identification was completed in only 8 h 22 min on average and with a concordance index of 95%.

## Conflict of interest

The authors declare that they have no conflicts of interest.

## Acknowledgements

We are very grateful to Dr. María Magdalena Peres from Becton Dickinson Argentina who generously provide us with Yeast-ID panels from the system BD Phoenix™.

## Appendix A. Integrantes de la Red de Micología-CABA

Ana Maria Romeo (Htal. Penna), Mariela Schijman (Htal. Álvarez), Claudia Garbasz (Htal Pirovano), Graciela Ponce (IREP), Silvana Cataldi (Htal Durand), Laura Dufranc (Htal Zubizarreta), Nora Franco (Htal. Piñero), Mónica López (Htal Ramos Mejía), Ricardo Iachini (I. Pasteur), Rosana Pereda (Htal P. Elizalde), Alicia Arechavala (Hospital Muñoz), Analía Fernandez (F. Favalaro), Silvia Relloso (CEMIC), Ivana Maldonado (Htal Aleman), Agustina Forastiero (Htal Británico), Norma Fernandez (Htal de Clinicas).

## References

1. Clinical and Laboratory Standards Institute (CLSI). L.S.I. M29-A3 protection of laboratory workers from occupationally acquired infections; approved guideline. 3rd ed; 2005. p. 25.
2. Córdoba S, Vivot W, Bosco-Borgeat M, Taverna C, Szusz W, Murisengo O, Isla G, Davel G, The Red Nacional de Laboratorios de Micología Argentina. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. *Rev Argent Microbiol.* 2011;43:176–85.
3. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. *Diagn Microbiol Infect Dis.* 2012;73:45–8.
4. Kanafani Z, Perfect J. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. *Clin Infect Dis.* 2008;46:120–8.
5. Kullberg B, Arendrup M. Invasive candidiasis. *N Engl J Med.* 2015;373:1445–56.
6. López Moral L, Tiraboschi I, Schijman M, Bianchi M, Guelfand L, Cataldi S. Integrantes de la Red de Micología de la Ciudad de Buenos Aires. Fungemias en hospitales de la Ciudad de Buenos Aires. *Rev Iberoam Micol.* 2012;29:144–9.
7. Nucci M, Thompson-Moya L, Guzman-Blanco M, Tiraboschi I, Cortes J, Echevarria J, Sifuentes J, Zurita J, Santolaya M, Alvarado Matute T, de Queiroz Telles F, Lopez Colombo A. Recomendaciones para el manejo de la candidemia en adultos en America Latina. *Rev Iberoam Micol.* 2013;30:150–7.
8. Pineda G, Scollo K, Santiso G, Lehmann E, Arechavala A. Aislamiento de *Candida dubliniensis* en distintos materiales clínicos. Análisis de métodos fenotípicos de diferenciación con *Candida albicans*. *Rev Argent Microbiol.* 2008;40:211–7.
9. Pontón J. Diagnóstico microbiológico de las micosis. *Rev Iberoam Micol.* 2002;19:25–9.
10. Procop G. Medically important fungi: a guide to identification, vol. 45, 5th ed. Lab Med; 2014. p. e68–9.
11. Relloso M, Nieves J, Fares Taie S, Farquharson V, Mujica M, Romano V, Zarate M, Smayevsky J. Evaluación de la espectrometría de masas: MALDI-TOF MS para la identificación rápida y confiable de levaduras. *Rev Argent Microbiol.* 2015;47:103–7.
12. Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. *Front Med.* 2016;3:11.
13. Van Herendael B, Bruynseel P, Bensaid M, Boekhout T, De Baere T, Surmont I, Mertens A. Validation of a modified algorithm for the identification of yeast isolates using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). *Eur J Clin Microbiol Infect Dis.* 2012;31:841–8.
14. Wadlin J, Hanko G, Stewart R, Pape J, Nachamkin I. Comparison of three commercial systems for identification of yeasts commonly isolated in the clinical microbiology laboratory. *J Clin Microbiol.* 1999;37:1967–70.